• LAVA Moderator: Shinji Ikari

the market: stocks, bonds, options, whatever



Gi38Kt-XwAA8Za7
 
Lol, China hits us right after the canada and mexico tariffs are delayed

Futures on the Dow Jones are down 200 points as of 12:31 AM Eastern Time after China announced the imposition of tariffs on select products from the US, including oil, LNG, agri machinery and coal. China will also be probing Google


 
Last edited:
Gen Z and their phones pretty much, plus expanding advertising more and more. I sold half at 12.80 and am going to maybe ride the rest until next quarter unless it goes to like 14 tomorrow morning
 
I'll sell and it'll be $50 18 months from now, lol. They have over 400M daily active users. The potential tiktok ban helped them, so that's something to pay attention to
 
Buy the dip
Money money money money money.

Is a MF joke made a Gran with 400 buyin/ swappin and selling.
BIT/ Ether/ Gold, In a year.
Imagine investing 4000, i d have 10.000 now. sad poor me.
But it was well spend, and made a lot of people happy.

Sharing is worth more then money,
however reinvesting probably smarter.

Btw i did buy in this dip, what goes down most of the times goes up,
eventually. I know a 96 who rich cause of me telling bout crypto.

Right after its invention.

Jumped right in, does not totally get it. But if you bought Bitcoins.
more then 20 years ago, your in. Or its a bubble.
You must evacuate before it blows.

So at least made someone else rich. Who had the balls to do it.
 
Last edited:
PLRX went down 35% today then got T1 halted 10 minutes ago in after hours for news pending. Obvious leaked info
 
Somebody knew ahead of the press release
Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendations by the trial’s independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF). Patients currently enrolled in BEACON-IPF will remain in the trial.

Enrollment and dosing have been paused while data is reviewed to understand the DSMB’s rationale for their recommendation. Blinding of the study will be maintained to preserve trial integrity. The Company has informed BEACON-IPF clinical trial investigators and is in the process of informing global regulatory authorities.
 
Top